🎉Finally out🎉 Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation ⁦ᅟᅟ ᅟ⁩ 🙏⁦Carmelo Gurnari⁩ ⁦Simona Pagliuca⁩ ⁦Christian Reinhardt⁩ et al. #mpnsm ashpublications.org/blood/article/…

A collection of clincally important insights in myeloma and MGUS. #MedTwitter 1/ Serum protein electrophoresis may underestimate the true size of the M protein when the level is too high. The gel saturates. So go by the quantitative IgG/IgA level to get a better estimate of M

#Amigotweetorials 1/9 Short Case 80♂️ Under Dermatologists for Pemphigus in a Medical Ward No Bleeding History Before Suddenly Starts to 🩸🩸after Venepuncture Nurse Calls the Medical Doctor and Some Basic Tests are Ordered👇 #hematology #blooducation #MedTwitter

😱Complications in hematology😱 Human herpes virus 6 (HHV-6) infection A short🧵 #MedTwitter 1/19

🎉Finally out🎉 We propose molecular monitoring + donor lymphocyte infusion as standard of care for relapsed myelofibrosis after BMT. 👉identifies patients early at molecular relapse 👉achieves deep responses 👉excellent outcome #mpnsm HemaSphere Journal (IF = 14.6) journals.lww.com/hemasphere/Ful…

1/9 EXAMPLE OF Hb-Hct DISCORDANCE Take a look at the values in the graphic. Without looking ahead in the thread, can you make a diagnosis?

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal ashpublications.org/bloodadvances/… by @MarkGeyerMD ➡️ Median time 5.5 yrs, to develop ALL ➡️ Assoc with TP53 and hypodiploidy. ➡️25/28 achieved CR/CRi, median OS around 3yr

Proud to share our work ⁦Cell Reports Medicine⁩ describing a target discovery pipeline for immunotherapy of multiple myeloma. #PernaLab #TargetDiscovery #Immunotherapy #myeloma #antibody #ILT3 #pipeline cell.com/cell-reports-m…

#alloHCT with younger matched unrelated donors (age ≤35 years) is associated with significantly decreased relapse risk & lower adjusted 5-year cumulative incidence of relapse compared to #alloHCT with older matched sibling donors (MSDs) (age ≥50 years). ow.ly/UoeB50PRsCE

Delighted to share our work now published on behalf of all co-authors. Our practice has changed- minimal use of HD-MTX in CNS prophylaxis in aNHL. Thank you so much to all international collaborators! ascopubs.org/doi/10.1200/JC…

Weekend review 📖 #ASH23, few selected #MDS abstracts to watch out at this year ASH meeting ASH #mdssm 🧵 👇🏽

A study found that #alloHCT is feasible after failure of chimeric antigen receptor T cell therapy (CAR-T) in patients with large B cell lymphoma. Read the full findings: ow.ly/be1h50QgAAO #CARTcells #Lymsm

#ASH23 The Benefit of Allogeneic Transplant in 1st CR in NPM1m AML with or without FLT3 ITD Is Restricted to Those Testing MRD + after Induction – an Analysis of the UK NCRI AML17 and AML19 Studies #leusm

Congrats Gunjan Shah Sergio Giralt on tour de force review about literally EVERYTHING you could want to know about ASCT in #mmsm: - MEL dosing - Mucositis strategies (Day -2 🧊) - Siltuximab prophylaxis - Wellness, including our life coaching RCT 🙏 sciencedirect.com/science/articl…

Weekend review 📖 What is the right duration of VENETOCLAX with HMA for AML: 7 days vs 14 days vs 21 days or 28 days? Brief review of literature in this 🧵 #leusm #AML

Thank you GvHD Hub for highlighting our results.. many thanks to my colleagues from several centers who help us with executing this study #Tandem24

Thrilled to present the work of the Perna Lab at #Tandem24 ⁦ASTCT⁩ Thank you Dr. Cathy Wu for the kind invitation 🙏🏻 tandem.confex.com/tandem/2024/me…

Junior colleagues asked 4 advice @ #tandem24 key strategy: Learn from patients, personal circumstances shape us, some r late bloomers trajectories differ, read read! be ur own mentor, ignore naysayers plenty around..start small but dream big! What's stopping you ?

Finally out ➡️ A huge shout out for Mark Litzow ECOG-ACRIN Cancer Research Group Mayo Clinic Comprehensive Cancer Center Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults | New England Journal of Medicine nejm.org/doi/full/10.10… ➡️ consolidation Blina improves OS in MRD-ve Ph-ve B-cell ALL

A new study published in Transplantation and Cellular Therapy Journal found that lower-dose MMF improved relapse rates and PFS in patients receiving haploidentical PBSCT with PTCy-based GvHD prophylaxis 📝 More news: gvhdhub.com #GvHD #MedNews #MedEd